Literature DB >> 17981646

PKC and Rho in vascular smooth muscle: activation by BOXes and SAH CSF.

Gail J Pyne-Geithman1, Sunil G Nair, Danielle N Caudell, Joseph F Clark.   

Abstract

Cerebral vasospasm (CV) remains a significant cause of delayed neurological deficit and ischemic damage after subarachnoid hemorrhage (SAH), despite intensive research effort. The current lack of an effective therapeutic approach is somewhat due to our lack of understanding regarding the mechanism by which this pathological constriction develops. Recent evidence implicates bilirubin oxidation products (BOXes) in the etiology of CV after SAH: BOXes are found in cerebrospinal fluid from SAH patients with symptomatic or angiographically visible vasospasm (CSFV) but not in CSF from SAH patients with no vasospasm (CSFC). We have previously published research suggesting that the etiology of CV comprises two components: a physiological stimulation to constrict and a pathological failure to relax. Both these components are elicited by CSFV, but not CSFC, and BOXes synthesized in the laboratory potentiate physiological constriction in arterial smooth muscle in vitro, and elicit contraction in pial arteries in vivo. In this paper, we will present our results concerning the action of BOXes on arterial smooth muscle constriction, compared with CSFV. We will also present evidence implicating temporal changes in PKC isoforms and Rho expression in both BOXes- and CSFV-elicited smooth muscle responses.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17981646      PMCID: PMC2430991          DOI: 10.2741/2778

Source DB:  PubMed          Journal:  Front Biosci        ISSN: 1093-4715


  62 in total

1.  Modulatory role of ERK MAPK-caldesmon pathway in PDGF-stimulated migration of cultured pulmonary artery SMCs.

Authors:  I A Yamboliev; W T Gerthoffer
Journal:  Am J Physiol Cell Physiol       Date:  2001-06       Impact factor: 4.249

2.  Intracellular calcium, myosin light chain phosphorylation, and contractile force in experimental cerebral vasospasm.

Authors:  W E Bulter; J W Peterson; N T Zervas; K G Morgan
Journal:  Neurosurgery       Date:  1996-04       Impact factor: 4.654

Review 3.  Phosphorylated synthetic peptides as tools for studying protein phosphatases.

Authors:  L A Pinna; A Donella-Deana
Journal:  Biochim Biophys Acta       Date:  1994-07-21

4.  Bilirubin production and oxidation in CSF of patients with cerebral vasospasm after subarachnoid hemorrhage.

Authors:  Gail J Pyne-Geithman; Chad J Morgan; Kenneth Wagner; Elizabeth M Dulaney; Janice Carrozzella; Daniel S Kanter; Mario Zuccarello; Joseph F Clark
Journal:  J Cereb Blood Flow Metab       Date:  2005-08       Impact factor: 6.200

5.  Time course of vasospasm in man.

Authors:  B Weir; M Grace; J Hansen; C Rothberg
Journal:  J Neurosurg       Date:  1978-02       Impact factor: 5.115

6.  Oral nimodipine reduces prostaglandin and thromboxane production by arteries chronically exposed to a periarterial haematoma and the antifibrinolytic agent tranexamic acid.

Authors:  J D Pickard; V Walker; J Vile; S Perry; P J Smythe; R Hunt
Journal:  J Neurol Neurosurg Psychiatry       Date:  1987-06       Impact factor: 10.154

7.  Endothelin-1-induced endothelin-1 release causes cerebral vasospasm in-vivo.

Authors:  M Zuccarello; A Romano; M Passalacqua; R M Rapoport
Journal:  J Pharm Pharmacol       Date:  1995-08       Impact factor: 3.765

8.  Delayed cerebral vasospasm is not reversible by aminophylline, nifedipine, or papaverine in a "two-hemorrhage" canine model.

Authors:  V G Varsos; T M Liszczak; D H Han; J P Kistler; J Vielma; P M Black; R C Heros; N T Zervas
Journal:  J Neurosurg       Date:  1983-01       Impact factor: 5.115

9.  Okadaic acid. Protein phosphatase inhibition and muscle contractile effects.

Authors:  A Takai
Journal:  J Muscle Res Cell Motil       Date:  1988-12       Impact factor: 2.698

10.  Participation of lipoxygenase products from arachidonic acid in the pathogenesis of cerebral vasospasm.

Authors:  T Watanabe; T Asano; T Shimizu; Y Seyama; K Takakura
Journal:  J Neurochem       Date:  1988-04       Impact factor: 5.372

View more
  8 in total

1.  Bilirubin oxidation end products directly alter K+ channels important in the regulation of vascular tone.

Authors:  Shangwei Hou; Rong Xu; Joseph F Clark; William L Wurster; Stefan H Heinemann; Toshinori Hoshi
Journal:  J Cereb Blood Flow Metab       Date:  2010-04-28       Impact factor: 6.200

Review 2.  Rho-associated coiled-coil-forming kinases (ROCKs): potential targets for the treatment of atherosclerosis and vascular disease.

Authors:  Qian Zhou; Christoph Gensch; James K Liao
Journal:  Trends Pharmacol Sci       Date:  2011-01-16       Impact factor: 14.819

Review 3.  The blood-brain barrier and the neurovascular unit in subarachnoid hemorrhage: molecular events and potential treatments.

Authors:  Peter Solár; Alemeh Zamani; Klaudia Lakatosová; Marek Joukal
Journal:  Fluids Barriers CNS       Date:  2022-04-11

4.  Lipocalin-type prostaglandin D synthase scavenges biliverdin in the cerebrospinal fluid of patients with aneurysmal subarachnoid hemorrhage.

Authors:  Takashi Inui; Mitsuhito Mase; Ryoko Shirota; Mariko Nagashima; Tetsuya Okada; Yoshihiro Urade
Journal:  J Cereb Blood Flow Metab       Date:  2014-07-09       Impact factor: 6.200

Review 5.  Biliverdin reductase: a target for cancer therapy?

Authors:  Peter E M Gibbs; Tihomir Miralem; Mahin D Maines
Journal:  Front Pharmacol       Date:  2015-06-03       Impact factor: 5.810

6.  A New Product of Bilirubin Degradation by H2O2 and Its Formation in Activated Neutrophils and in an Inflammatory Mouse Model.

Authors:  Fei-Fei Yu; Yao Yuan; Yan Ao; Li Hua; Wu Wang; Yiyi Cao; Jing Xi; Yang Luan; Shangwei Hou; Xin-Yu Zhang
Journal:  Biomolecules       Date:  2022-09-04

7.  Genetics of cerebral vasospasm.

Authors:  Travis R Ladner; Scott L Zuckerman; J Mocco
Journal:  Neurol Res Int       Date:  2013-04-11

8.  Bilirubin Oxidation Products and Cerebral Vasoconstriction.

Authors:  Robert M Rapoport
Journal:  Front Pharmacol       Date:  2018-04-27       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.